Cathleen M. McCabe, MD
Show Description +
Cathleen M. McCabe, MD, reports on the significant improvements in patient-reported outcomes with Vuity (pilocarpine HCl ophthalmic solution 1.25%, Allergan) versus a vehicle in GEMINI 1 and GEMINI 2, two pivotal phase 3 clinical studies evaluating the efficacy, safety, and tolerability of the agent for the treatment of presbyopia.
Posted: 11/14/2021
Cathleen M. McCabe, MD
Cathleen M. McCabe, MD, reports on the significant improvements in patient-reported outcomes with Vuity (pilocarpine HCl ophthalmic solution 1.25%, Allergan) versus a vehicle in GEMINI 1 and GEMINI 2, two pivotal phase 3 clinical studies evaluating the efficacy, safety, and tolerability of the agent for the treatment of presbyopia.
Posted: 11/14/2021
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2021.
Please log in to leave a comment.